Search Results 1141-1150 of 11193 for Antifungal Resistance
intercurrent illness requiring antibiotic/antiviral/antifungal therapy or interventional procedures. Participants with infections unlikely to be resolved
Presence of any active infections (excluding fungal or bacterial infections that require only topical antimicrobials) including, but not limited to, those ...
Concurrent treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers that can include antifungals. Also, because of their effect as ...
Skalski, M.D., discusses research into intestinal bacterial and fungal microbiota in patients with obstructive disease phenotypes. April 03, 2020. Update on ICU ...
The purpose of this study is to determine the effetiveness and safety of brepocitinib (a tyrosine kinase [TYK] 2/Janus kinase [JAK] 1 inhibitor) in patients ...
About this study. This randomized pilot clinical trial studies whether auranofin will relieve pain following paclitaxel in patients who have previously ...
Selinexor is FDA approved when given with dexamethasone for previously treated relapsed multiple myeloma. Selinexor is currently being studied in DLBCL and ...
About this study. The purpose of this study is to characterize the presence and level of SBT777101-reactive antigen in synovial biopsy tissue and fluid from ...
"There is a fair amount of evidence that exercise, aerobic exercise — maybe some resistance training, as well — can actually slow the progression or delay ...
A Mayo Clinic study of patients with inflammatory bowel disease (IBD) has found that Janus kinase (JAK) inhibitors aren't associated with an increased risk ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.